1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Why AZ Respiratory Head Believes Third-Placed Benralizumab Can Conquer Market

 
• By Sten Stovall

AstraZeneca hopes its investigative biologic benralizumab has strongly differentiated itself from rival therapies Nucala and Cinqair with the detailed publication of Phase III data showing it significantly cut exacerbations and improved lung function and symptoms in patients with severe eosinophilic asthma, as well as offering a favorable dosing schedule.

Lung model

Details of Phase III trials for AstraZeneca PLC’s first biologic respiratory medicine benralizumab released at the European Respiratory Society International Congress on Sept. 5 show the monoclonal antibody directly and quickly killed inflammatory cells called eosinophils which drive inflammation and airway hyper-responsiveness in around 50% of asthma patients.

In an interview with Scrip, Tom Keith-Roach, who leads AstraZeneca’s respiratory, inflammation and autoimmune business, was optimistic about the product's market prospects, arguing that the drug's potential for reduced dosing frequency gives it a competitive advantage over rival therapies from GlaxoSmithKline PLC and Teva

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.